Shots:
Processa & Intact have entered into a binding term sheet for granting Intact an exclusive option to license PCS12852 for gastroparesis & other GI motility disorders
As per the deal, Processa will receive a 3.5% equity in Intact at closing, $2.5M option fee, ~$20M in development & regulatory milestones, ~$432.5M in commercial milestones, &…
Shots:
Gastroparesis is a chronic gastrointestinal disorder characterized by delayed gastric emptying, leading to symptoms such as nausea, vomiting, bloating, and early satiety. This condition significantly affects patients' quality of life, posing challenges for diagnosis and treatment.
Our Disease of the Month report covers epidemiology, market size, current management strategies, emerging therapeutic options, and the…
Gastroparesis is a chronic disease affecting the motility of the stomach muscles. It refers to partial paralysis of the stomach. It usually occurs due to nerve injury including vagus nerve damage. Normally the strong muscular contractions of vagus nerve move the food through the digestive tract, but in the case of gastroparesis, this spontaneous movement…

